Show simple item record

AuthorKhan, Muhammad Yasir
AuthorAljehani, Najwa D.
AuthorAbdulal, Rwaa H.
AuthorGhazwani, Aishah
AuthorAlsulaiman, Reem M.
AuthorEyouni, Mais
AuthorShebbo, Salima
AuthorBasabrain, Mohammad
AuthorSanki, Mohammad A.
AuthorAlsharef, Asem A.
AuthorAbdulaal, Wesam H.
AuthorAlbukhari, Ashwag
AuthorQadri, Ishtiaq
AuthorAlluhaybi, Khalid A.
AuthorAltorki, Tarfa
AuthorAlhabbab, Rowa
AuthorAlghanmi, Maimonah
AuthorZawawi, Ayat
AuthorAbujamel, Turki S.
AuthorAlgaissi, Abdullah
AuthorThulasi Raman, Sathya N.
AuthorAlfaleh, Mohamed A.
AuthorAlghamdi, Badrah S.
AuthorAzhari, Ala A.
AuthorLi, Xuguang
AuthorMahmoud, Ahmad Bakur
AuthorHashem, Anwar M.
Available date2025-11-27T09:20:04Z
Publication Date2026-01-01
Publication NameVaccine
Identifierhttp://dx.doi.org/10.1016/j.vaccine.2025.127975
CitationKhan, Muhammad Yasir, Najwa D. Aljehani, Rwaa H. Abdulal, Aishah Ghazwani, Reem M. Alsulaiman, Mais Eyouni, Salima Shebbo et al. "Intranasal CD40-targeted recombinant MERS-CoV S1 protein is superior to intramuscular immunization in eliciting systemic and mucosal immune responses in mice." Vaccine 69 (2026): 127975.
ISSN0264410X
URIhttps://www.sciencedirect.com/science/article/pii/S0264410X25012733
URIhttp://hdl.handle.net/10576/68824
AbstractThe Middle East respiratory syndrome coronavirus (MERS-CoV) is a global One Health challenge with a potential pandemic threat, with no approved vaccines or antiviral drugs available to date. Thus, there is an urgent need for a safe and effective vaccine. Herein, we developed a recombinant subunit self-adjuvanted fusion protein vaccine targeting the MERS-CoV S1 subunit to CD40-expessing APCs (S1-F/CD40L). We found that intramuscular injection of S1-F/CD40L in conjunction with Alum and CpG was superior to Alum or CpG alone in terms of systemic Ag-specific humoral and cellular responses and Th1-dominant phenotype. Furthermore, the immunogenicity of co-adjuvanted S1-F/CD40L was compared to that of S1 alone via both intramuscular and intranasal immunization. Two intramuscular and intranasal doses of S1-F/CD40L and S1 were immunogenic in eliciting systemic and mucosal humoral and cellular immunity, including IgG, IgA, neutralizing antibodies (nAbs), and T cell responses in mice, with a greater response in the CD40-targeted S1 group. Intranasal vaccination with S1-F/CD40L induced systemic humoral and cellular immune responses comparable to those induced by intramuscular vaccination, including binding and nAbs and T cell responses. Importantly, intranasal vaccine was able to elicit significantly higher local mucosal humoral and cellular immune responses in mouse lungs and markedly elevated circulating IgA levels compared to intramuscular vaccination. Collectively, our results suggest that the S1-F/CD40L vaccine co-adjuvanted with Alum and CpG can be used as an effective and safe mucosal candidate vaccine against MERS-CoV. Furthermore, these data demonstrate that the incorporation of CD40L as APCs targeting ligand and molecular adjuvant enhances immunogenicity, thus offering a promising platform that could be explored further to respond to future emerging pathogens and possible outbreaks.
SponsorThis work was funded by Community Jameel - Saudi Arabia under Jameel Fund for Infectious Disease Research and Innovation under grant no. JML: 004-141-2024. The authors would also like to thank the Deanship of Scientific Research (DSR) at King Abdulaziz University, Jeddah, Saudi Arabia for their support.
Languageen
PublisherElsevier
SubjectMERS-CoV
Intranasal
Intramuscular
CD40L
Adjuvants
Antigen-presenting cells
TitleIntranasal CD40-targeted recombinant MERS-CoV S1 protein is superior to intramuscular immunization in eliciting systemic and mucosal immune responses in mice
TypeArticle
Volume Number69
Open Access user License http://creativecommons.org/licenses/by/4.0/
ESSN1873-2518
dc.accessType Full Text


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record